Advertisement Pharmaceutical Business review - Page 1525 of 5282 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 16, 2026

Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy

Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND) application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.

HBM7575/SKB575 blocks the interaction between TSLP and its receptor, inhibiting signalling pathways and Th2 immune cell activation. Credit: alicancomertpay / Shutterstock.com.